This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ehrhardt, J. Search for Related Content PubMed Articles by Ehrhardt, J. Social Bookmarking                         What's this?

What School Nurses Need to Know About Cervical Cancer, HPV, and the New Vaccine

Jeanie Ehrhardt, RN, BSN, is a graduate student in the nurse practitioner program at South Florida University, Tampa, FL

At least 12,000 women are diagnosed with cervical cancer each year in the United States, accounting for at least 4,000 deaths. Worldwide, cervical cancer is the second most common type of cancer among women. The human papilloma virus (HPV) has been linked to at least 70% of all cervical cancer. HPV can be divided into 2 categories: (a) low risk, which is responsible for genital warts, and (b) high risk, which is responsible for cervical cancer. An effective new vaccine has been approved that will decrease the spread of infection caused by HPV, therefore decreasing the future incidence of cervical cancer and genital warts. Understanding the risks of acquiring HPV and the increased risk for cervical cancer may lead to enhanced vaccine acceptance.

Key Words: cervical cancer • Gardasil • genital warts • human papilloma virus • vaccine

The Journal of School Nursing, Vol. 23, No. 6, 310-314 (2007)
DOI: 10.1177/10598405070230060201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?